A new vaccine approach for treating glioblastoma
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
['FUNDING_R01'] · UNIVERSITY OF FLORIDA · NIH-10687969
This study is testing a new vaccine that uses tiny particles to help your immune system fight glioblastoma, a tough type of brain cancer, and it's designed to make your body respond better to the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-10687969 on ClinicalTrials.gov |
What this research studies
This research investigates a novel vaccine formulation designed to enhance the immune response against glioblastoma, a highly aggressive brain cancer. The vaccine uses RNA-lipid nanoparticles to deliver tumor mRNA, mimicking a viral infection to stimulate the body's immune system. By activating dendritic cells and inducing glioma-specific T cell immunity, the approach aims to improve patient outcomes significantly. The research has shown promising results in animal models, demonstrating safety and potential efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently been diagnosed with glioblastoma and are seeking new treatment options.
Not a fit: Patients with glioblastoma who are not newly diagnosed or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option that significantly extends survival for patients with glioblastoma.
How similar studies have performed: Previous research has shown success with similar RNA-lipid nanoparticle approaches in animal models, indicating potential for human application.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAYOUR, ELIAS — UNIVERSITY OF FLORIDA
- Study coordinator: SAYOUR, ELIAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.